Warfarin Drug-Drug Interactions Requiring Clinical Monitoring
Warfarin exposure is affected by many drugs via CYP450 effects and by additive bleeding risk through pharmacodynamic mechanisms. INR changes and bleeding can occur when interacting drugs are started or stopped, so INR should be monitored more frequently during these transitions [1], [2].
High-Risk Interaction Classes to Watch For
Enzyme inhibitors and inducers affecting warfarin metabolism
Closer INR monitoring is required when interacting drugs inhibit or induce CYP pathways relevant to warfarin disposition [1].
Common CYP2C9 inhibitors (warfarin potentiation risk)
- Amiodarone [1]
- Cotrimoxazole (trimethoprim-sulfamethoxazole) [1]
- Metronidazole [1]
- Fluconazole [1]
- Voriconazole [1]
Common CYP2C9 inducers (warfarin inhibition risk)
- Rifampin [1]
- Phenobarbital [1]
- Carbamazepine [1]
Antibiotics and antifungals
Clinical pharmacokinetic studies have not shown consistent effects on warfarin plasma concentrations across antibiotics and antifungals. INR changes have been reported, so INR should be monitored when starting or stopping any antibiotic or antifungal in patients taking warfarin [1].
Drugs increasing bleeding risk (pharmacodynamic additive effects)
Bleeding risk increases when warfarin is co-administered with drugs that increase bleeding risk, so close monitoring is recommended when such drugs are used with warfarin [1].
Examples of bleeding-risk classes
- Other anticoagulants (e.g., heparin, direct thrombin inhibitors, etc.) [1]
- Antiplatelet agents and NSAIDs are associated with increased bleeding risk due to additive effects on hemostasis [3], [4]
Key “Common in Practice” Interaction Examples
Amiodarone
Amiodarone potentiates warfarin effect and requires close INR monitoring when added or discontinued because of its prolonged time course [5], [1].
Trimethoprim-sulfamethoxazole and metronidazole
These agents are among CYP2C9 inhibitors listed in the FDA label and are associated with INR increases, requiring closer INR monitoring [1].
Azole antifungals
Fluconazole and voriconazole appear as CYP2C9 inhibitors in the FDA label and are associated with increased warfarin anticoagulant effect risk [1].
Initiation/Discontinuation Monitoring Triggers
More frequent INR monitoring is recommended when other drugs are started or stopped, including botanicals, and when doses of other drugs change [1].
Target-Related Safety Thresholds That Affect Monitoring Intensity
An INR greater than 4.0 is associated with higher bleeding risk and no additional therapeutic benefit in most patients, so supratherapeutic INR values should prompt intensified safety actions and monitoring [1].
Common Pitfalls to Avoid
- Assuming antibiotics do not affect INR because pharmacokinetic effects may be inconsistent across agents. INR changes are reported, so monitoring is still required when antibiotics or antifungals are started or stopped [1].
- Overlooking pharmacodynamic bleeding risk from NSAIDs or antiplatelet therapy. These combinations increase bleeding risk even when INR does not increase substantially [3], [4].
- Not recognizing that adding or stopping amiodarone can require prolonged INR monitoring due to its long time course [5].
Practical Interaction Watch List (Quick Reference)
- CYP2C9 inhibitors: amiodarone, cotrimoxazole, metronidazole, fluconazole, voriconazole [1]
- CYP2C9 inducers: rifampin, carbamazepine, phenobarbital [1]
- Antibiotics and antifungals: INR monitoring on start/stop [1]
- Additive bleeding-risk agents: NSAIDs, antiplatelet agents, and other anticoagulants [1], [3]